Compare Kroger Co (KR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Eli Lilly And Co — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 28.7× Kroger Co's market cap, and Kroger Co pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Eli Lilly And Co for 93 Days on average.
| KR | LLY | |
|---|---|---|
Market Cap | $36.27B | $1.04T |
Volume | 8,301,523 | 3,064,878 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $1.28K |
52-Week Low | $55.53 | $799.57 |
Typical Hold Time | 108 Days | 93 Days |
Enterprise Value | $57.69B | $1.09T |
Dividend Yield | 2.54% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.64, up 4.03% today, with a bullish technical signal supported by moving averages. The stock shows mixed fundamentals with a low P/S ratio of 0.26 but elevated P/E of 33.19, while recent earnings beat expectations in two of the last three quarters. Analyst consensus is moderately bullish with a $70.62 price target, representing 14.6% upside potential from current levels.
Kroger offers value through its low valuation multiples and consistent dividends, but faces headwinds from competitive pressures and integration risks from pending acquisitions. The company's digital growth initiatives and retail media expansion provide growth catalysts, though margin compression remains a concern amid rising costs and softer sales guidance for fiscal 2026.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
